Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was downgraded by Bank of America from a "buy" rating to a "neutral" rating in a report released on Tuesday, MarketBeat reports. They presently have a $18.00 price target on the stock, down from their prior price target of $32.00. Bank of America's target price suggests a potential upside of 32.74% from the stock's current price.

Several other brokerages have also weighed in on KROS. Wells Fargo & Company decreased their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. HC Wainwright lowered their price objective on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Truist Financial decreased their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Finally, Scotiabank lowered their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $30.56.

Keros Therapeutics Stock Down 0.6%

Shares of KROS stock traded down $0.08 during mid-day trading on Tuesday, reaching $13.56. The stock had a trading volume of 377,905 shares, compared to its average volume of 863,238. Keros Therapeutics has a one year low of $9.12 and a one year high of $72.37. The firm has a market cap of $550.74 million, a PE ratio of -2.60 and a beta of 1.31. The firm's 50 day simple moving average is $13.81 and its 200 day simple moving average is $16.81.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period last year, the business earned ($1.21) earnings per share. Sell-side analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 20.60% of the company's stock.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its position in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after buying an additional 182,314 shares during the last quarter. Darwin Global Management Ltd. lifted its stake in shares of Keros Therapeutics by 10.7% during the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after acquiring an additional 163,403 shares during the period. Norges Bank acquired a new position in shares of Keros Therapeutics during the fourth quarter valued at $1,027,000. Two Sigma Investments LP boosted its holdings in Keros Therapeutics by 226.1% in the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock valued at $533,000 after acquiring an additional 23,342 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Keros Therapeutics in the fourth quarter worth about $730,000. Institutional investors and hedge funds own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.